SG10202111952PA - Combination therapy with controlled-release cnp agonists - Google Patents
Combination therapy with controlled-release cnp agonistsInfo
- Publication number
- SG10202111952PA SG10202111952PA SG10202111952PA SG10202111952PA SG10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA
- Authority
- SG
- Singapore
- Prior art keywords
- controlled
- combination therapy
- release cnp
- cnp agonists
- agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191456 | 2016-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202111952PA true SG10202111952PA (en) | 2021-12-30 |
Family
ID=57047055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111952PA SG10202111952PA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
| SG11201901534VA SG11201901534VA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901534VA SG11201901534VA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11564974B2 (sr) |
| EP (2) | EP4223309A1 (sr) |
| JP (1) | JP7189133B2 (sr) |
| KR (2) | KR102531327B1 (sr) |
| CN (1) | CN109843295B (sr) |
| AU (2) | AU2017336253B2 (sr) |
| BR (1) | BR112019005351A2 (sr) |
| CA (1) | CA3037448A1 (sr) |
| DK (1) | DK3518930T3 (sr) |
| ES (1) | ES2943013T3 (sr) |
| FI (1) | FI3518930T3 (sr) |
| HR (1) | HRP20230385T1 (sr) |
| HU (1) | HUE062117T2 (sr) |
| IL (3) | IL305975A (sr) |
| LT (1) | LT3518930T (sr) |
| MA (1) | MA46430B1 (sr) |
| MX (1) | MX2019003173A (sr) |
| NZ (1) | NZ751746A (sr) |
| PL (1) | PL3518930T3 (sr) |
| PT (1) | PT3518930T (sr) |
| RS (1) | RS64203B1 (sr) |
| RU (1) | RU2768747C2 (sr) |
| SG (2) | SG10202111952PA (sr) |
| SI (1) | SI3518930T1 (sr) |
| WO (1) | WO2018060314A1 (sr) |
| ZA (1) | ZA201901810B (sr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| HRP20221339T1 (hr) | 2016-01-08 | 2023-01-06 | Ascendis Pharma Growth Disorders A/S | Cnp predlijekovi s učvršćenjem nosača na cikličkom dijelu peptida |
| EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| MX2018008061A (es) * | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| US20200276276A1 (en) * | 2016-03-01 | 2020-09-03 | Ascendis Pharma Bone Diseases A/S | PTH Prodrugs |
| FI3518960T3 (fi) | 2016-09-29 | 2023-10-04 | Ascendis Pharma Bone Diseases As | Annostusohjelma kontrolloidusti vapautuvalle PTH-yhdisteelle |
| CA3037448A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
| MX2019003182A (es) | 2016-09-29 | 2019-08-05 | Ascendis Pharma Bone Diseases As | Compuestos de hormona paratiroidea con bajas relaciones pico - valle. |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0892789T2 (sl) | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
| AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| CA2345414A1 (en) | 1998-09-28 | 2000-04-06 | Santen Pharmaceutical Co., Ltd. | Eyedrops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as active ingredient |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
| ES2516041T3 (es) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH) |
| US7054679B2 (en) | 2001-10-31 | 2006-05-30 | Robert Hirsh | Non-invasive method and device to monitor cardiac parameters |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| BR0316560A (pt) * | 2002-11-26 | 2005-10-04 | Nobex Corp | Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| US8377917B2 (en) | 2004-03-23 | 2013-02-19 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (es) | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| WO2008031045A2 (en) | 2006-09-08 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| JP2010503707A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
| AR063621A1 (es) | 2006-11-09 | 2009-02-04 | Alcon Res Ltd | Matriz polimerica insoluble en agua para la administracion de farmacos |
| KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| EA021222B8 (ru) | 2007-06-21 | 2015-11-30 | ИксЭль-ПРОТЕИН ГМБХ | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro |
| CA2693616A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| US8377884B2 (en) | 2007-11-21 | 2013-02-19 | Biomarin Pharmaceutical Inc. | Variants of C-type natriuretic peptides |
| MX2010008024A (es) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Profarmaco que comprende un enlazador que se puede separar por si mismo. |
| WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| WO2010033216A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| DK2393828T3 (en) | 2009-02-03 | 2017-01-23 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
| PE20120792A1 (es) | 2009-05-20 | 2012-07-27 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
| WO2011012715A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| WO2011082368A2 (en) | 2009-12-31 | 2011-07-07 | Enzon Pharmaceuticals, Inc | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| US8946405B2 (en) | 2010-05-05 | 2015-02-03 | Prolynx Llc | Controlled release from solid supports |
| EP2571510B1 (en) | 2010-05-21 | 2018-08-08 | XL-protein GmbH | Biosynthetic proline/alanine random coil polypeptides and their uses |
| WO2012002047A1 (ja) | 2010-06-30 | 2012-01-05 | Ｎｅｃソフト株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
| EP3643306A3 (en) | 2011-08-12 | 2020-08-26 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| CN103857413A (zh) | 2011-08-12 | 2014-06-11 | 阿森迪斯药物股份有限公司 | 载体连接的曲罗尼尔前药 |
| CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
| WO2013024047A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| TWI578995B (zh) * | 2012-04-25 | 2017-04-21 | 第一三共股份有限公司 | 利尿鈉肽受體npr-b促效劑之用途 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| EP2906617B1 (en) | 2012-10-11 | 2018-03-14 | Ascendis Pharma A/S | Hydrogel prodrugs |
| EP2908845A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Fatty acid acylated amino acids for growth hormone delivery |
| JP6536871B2 (ja) | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法 |
| JPWO2015129812A1 (ja) | 2014-02-27 | 2017-03-30 | 第一三共株式会社 | ステロイド剤投与で誘発される成長障害に対する医薬 |
| KR102608645B1 (ko) | 2014-11-18 | 2023-12-01 | 아센디스 파마 엔도크리놀로지 디비전 에이/에스 | 신규한 중합체성 hGH 프로드러그 |
| US20170368189A1 (en) | 2015-01-09 | 2017-12-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
| US11202819B2 (en) | 2015-12-08 | 2021-12-21 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat osteoarthritis |
| HRP20221339T1 (hr) | 2016-01-08 | 2023-01-06 | Ascendis Pharma Growth Disorders A/S | Cnp predlijekovi s učvršćenjem nosača na cikličkom dijelu peptida |
| IL293979B1 (en) | 2016-01-08 | 2024-04-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with increased NEP stability |
| AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| US20200276276A1 (en) | 2016-03-01 | 2020-09-03 | Ascendis Pharma Bone Diseases A/S | PTH Prodrugs |
| CA3037448A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
| WO2020037285A1 (en) | 2018-08-16 | 2020-02-20 | Beyondspring Pharmaceuticals, Inc. | Method and composition for stimulating immune response |
| US20220118053A1 (en) | 2019-02-11 | 2022-04-21 | Ascendis Pharma Growth Disorders A/S | Dry Pharmaceutical Formulations of CNP Conjugates |
-
2017
- 2017-09-28 CA CA3037448A patent/CA3037448A1/en active Pending
- 2017-09-28 JP JP2019516647A patent/JP7189133B2/ja active Active
- 2017-09-28 EP EP23159718.8A patent/EP4223309A1/en active Pending
- 2017-09-28 HU HUE17781429A patent/HUE062117T2/hu unknown
- 2017-09-28 HR HRP20230385TT patent/HRP20230385T1/hr unknown
- 2017-09-28 IL IL305975A patent/IL305975A/en unknown
- 2017-09-28 NZ NZ751746A patent/NZ751746A/en unknown
- 2017-09-28 ES ES17781429T patent/ES2943013T3/es active Active
- 2017-09-28 PL PL17781429.0T patent/PL3518930T3/pl unknown
- 2017-09-28 DK DK17781429.0T patent/DK3518930T3/da active
- 2017-09-28 AU AU2017336253A patent/AU2017336253B2/en active Active
- 2017-09-28 SG SG10202111952PA patent/SG10202111952PA/en unknown
- 2017-09-28 LT LTEPPCT/EP2017/074596T patent/LT3518930T/lt unknown
- 2017-09-28 SI SI201731339T patent/SI3518930T1/sl unknown
- 2017-09-28 WO PCT/EP2017/074596 patent/WO2018060314A1/en unknown
- 2017-09-28 IL IL290054A patent/IL290054B2/en unknown
- 2017-09-28 MX MX2019003173A patent/MX2019003173A/es unknown
- 2017-09-28 FI FIEP17781429.0T patent/FI3518930T3/fi active
- 2017-09-28 BR BR112019005351A patent/BR112019005351A2/pt unknown
- 2017-09-28 KR KR1020197012470A patent/KR102531327B1/ko active IP Right Grant
- 2017-09-28 EP EP17781429.0A patent/EP3518930B1/en active Active
- 2017-09-28 RS RS20230385A patent/RS64203B1/sr unknown
- 2017-09-28 PT PT177814290T patent/PT3518930T/pt unknown
- 2017-09-28 SG SG11201901534VA patent/SG11201901534VA/en unknown
- 2017-09-28 RU RU2019112897A patent/RU2768747C2/ru active
- 2017-09-28 KR KR1020237015410A patent/KR20230066147A/ko not_active Application Discontinuation
- 2017-09-28 CN CN201780058524.8A patent/CN109843295B/zh active Active
- 2017-09-28 US US16/338,185 patent/US11564974B2/en active Active
- 2017-09-28 MA MA46430A patent/MA46430B1/fr unknown
-
2019
- 2019-03-25 IL IL265592A patent/IL265592B/en unknown
- 2019-03-25 ZA ZA2019/01810A patent/ZA201901810B/en unknown
-
2022
- 2022-12-22 US US18/145,676 patent/US20230302091A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201709A patent/AU2023201709A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290054A (en) | Combined treatment with cnp agonists with controlled release | |
| IL263521A (en) | Combination therapy | |
| HK1259384A1 (zh) | 具有增加的nep穩定性的控制釋放cnp激動劑 | |
| IL259658A (en) | Controlled-release cnp agonists with reduced side effects | |
| IL259827A (en) | Controlled-release cnp agonists with low initial npr-b activity | |
| IL265406B (en) | combined treatment | |
| GB201608797D0 (en) | Therapeutic use | |
| GB201604318D0 (en) | Combination therapy | |
| GB201604316D0 (en) | Combination therapy | |
| IL265340A (en) | Combination therapy | |
| GB201609735D0 (en) | Combination therapy | |
| GB201603653D0 (en) | Combination Therapy | |
| GB201706223D0 (en) | Combination therapy | |
| GB201706228D0 (en) | Combination therapy | |
| GB201706235D0 (en) | Combination therapy | |
| GB201706234D0 (en) | Combination therapy | |
| GB201706233D0 (en) | Combination therapy | |
| GB201706232D0 (en) | Combination therapy | |
| GB201706231D0 (en) | Combination therapy | |
| GB201706221D0 (en) | Combination therapy | |
| GB201706225D0 (en) | Combination therapy | |
| GB201706224D0 (en) | Combination therapy | |
| GB201706230D0 (en) | Combination therapy | |
| GB201706222D0 (en) | Combination therapy | |
| GB201706226D0 (en) | Combination therapy |